

From: [Trials](#)
To: [Jihong Lou](#); [Trials](#)
Cc: [Houston, Michael R.](#); [Brown, Dan](#); [Rieger, Sarah E.](#); [Fernandes, Jolene S.](#); [682IPR](#); [Nick Cerrito](#); [Frank Calvosa](#); [Catherine Mattes](#); [Stacy Redman](#)
Subject: RE: IPR2022-01531, Synaffix v. Hangzhou DAC Biotech
Date: Monday, May 12, 2025 4:50:08 PM

Counsel,

The panel authorizes the parties' joint request to modify Due Dates 5, 6, and 7 to May 19, 23, and 27, respectively, as requested in the panels' joint email of May 12, 2005. Entry of this email into the record as an exhibit constitutes the panel's order on this issue.

Regards,

Andrew Kellogg,
Deputy Chief Clerk, Trials
Patent Trial and Appeal Board
USPTO
andrew.kellogg@uspto.gov
(571) 272-5366

From: Jihong Lou <jihonglou@quinnemanuel.com>
Sent: Monday, May 12, 2025 7:52 AM
To: Trials <Trials@USPTO.GOV>
Cc: Houston, Michael R. <MHouston@foley.com>; Brown, Dan <dbrown@foley.com>; Rieger, Sarah E. <srieger@foley.com>; Fernandes, Jolene S. <jfernandes@foley.com>; 682IPR <682ipr@foley.com>; Nick Cerrito <nickcerrito@quinnemanuel.com>; Frank Calvosa <frankcalvosa@quinnemanuel.com>; Catherine Mattes <catherinemattes@quinnemanuel.com>; Jihong Lou <jihonglou@quinnemanuel.com>; Stacy Redman <stacyredman@quinnemanuel.com>
Subject: IPR2022-01531, Synaffix v. Hangzhou DAC Biotech

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Your Honors:

The parties jointly write to the Board to request entry of an order to extend Due Dates 5, 6, and 7 for an anticipated motion to exclude evidence relating to two exhibits. Specifically, pursuant to the Board's April 4, 2025 Order (Paper 40), Patent Owner filed its sur-reply with an expert declaration by its expert Dr. Lawrence Nathan Tumey on April 25, 2025, and Petitioner deposed Dr. Tumey on May 9, 2025. During that May 9, 2025 deposition, Petitioner introduced two new exhibits, Exhibits 1089 and 1090, and Patent Owner objected to the new exhibits during and after the deposition. Petitioner intends to submit Exhibits 1089 and 1090 when filing its sur-sur-reply on May 16, 2025. Patent Owner intends to file a motion to exclude Exhibits 1089 and 1090 and related deposition

testimony shortly thereafter. Petitioner does not believe that it is appropriate to exclude the exhibits, but Petitioner does not oppose the proposed schedule changes if it is appropriate to address this issue via the motion to exclude process. The parties have met and conferred and have agreed to the following schedule for Patent Owner's motion to exclude Petitioner's Exhibits 1089 and 1090 and related deposition testimony. This proposed extension does not apply to any other motion to exclude any other evidence by either party.

Event	Current Due Date	Proposed Due Date
Motion to exclude Exhibits 1089 and 1090 and related deposition testimony (Due Date 5)	May 9, 2025	May 19, 2025
Opposition to the above motion to exclude (Due Date 6)	May 16, 2025	May 23, 2025
Reply to the above opposition to motion to exclude (Due Date 7)	May 23, 2025	May 27, 2025

Because the proposed schedule slightly extends Due Date 7, from Friday, May 23, 2025, to Tuesday, May 27, 2025 (the day after the Memorial Day), the parties seek the Board's permission to extend Due Date 7 and to issue an order to extend the due dates as proposed above.

Should the Board desire that the parties provide more detail on the bases for this request, the parties will do so. Should the Board wish to hold a conference call concerning this request, the parties can revert with our availabilities.

Respectfully submitted,
Counsel for Patent Owner DAC and Counsel for Petitioner Synaffix

Jihong Lou
Associate,
Quinn Emanuel Urquhart & Sullivan, LLP

1300 I Street, NW, Suite 900
Washington, D.C. 20005
202-538-8367 Direct
202.538.8000 Main Office Number
202.538.8100 FAX
jihonglou@quinnemanuel.com
www.quinnemanuel.com

NOTICE: The information contained in this e-mail message is intended only for the personal and confidential use of the recipient(s) named above. This message may be an attorney-client communication and/or work product and as such is privileged and confidential. If the reader of this message is not the intended recipient or agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by e-mail, and delete the original message.